EE426 Budget Impact Analysis of Atezolizumab in 1ST Line Treatment for Patients With PD-L1 High Metastatic NSCLC From a French Payor Perspective

EE426 Budget Impact Analysis of Atezolizumab in 1ST Line Treatment for Patients With PD-L1 High Metastatic NSCLC From a French Payor Perspective

Saved in:
Bibliographic Details
Published in:Value in health Vol. 25; no. 12; p. S139
Main Authors: Benyounes, K, Delzard, M, Le Lay, K, Bianic, F, Bougeard, C
Format: Journal Article
Language:English
Published: Elsevier Inc 01-12-2022
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2022.09.672